The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity

Kitazawa,Fumiaki; Kado,Yoko; Ueda,Kumi; Kokufu,Takatoshi; Fuchida,Shin‑Ichi; Okano,Akira; Hatsuse,Mayumi; Murakami,Satoshi; Nakayama,Yuko; Takara,Kohji; Shimazaki,Chihiro

doi:10.3892/mco.2015.683

The interaction between oral melphalan and gastric antisecretory drugs: Impact on clinical efficacy and toxicity

Authors:
- Fumiaki Kitazawa
- Yoko Kado
- Kumi Ueda
- Takatoshi Kokufu
- Shin‑Ichi Fuchida
- Akira Okano
- Mayumi Hatsuse
- Satoshi Murakami
- Yuko Nakayama
- Kohji Takara
- Chihiro Shimazaki
View Affiliations

Affiliations: Department of Pharmacy, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Kyoto 603‑8151, Japan, Department of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Kyoto 603‑8151, Japan, Department of Clinical Pharmaceutics, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, Himeji, Hyogo 670‑8524, Japan
Published online on: November 20, 2015 https://doi.org/10.3892/mco.2015.683
Pages: 293-297

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to clarify whether gastric antisecretory drugs affect the clinical efficacy and toxicity of orally administered melphalan in patients with multiple myeloma. A total of 10 patients receiving bortezomib plus oral melphalan and prednisolone (VMP) therapy between December 2011 and November 2014 were analyzed retrospectively. The patients were divided into a control group (seven patients) and a concomitant group (three patients, who were also administered with gastric antisecretory drugs). The gastric antisecretory drugs included rabeprazole sodium (two patients) and famotidine (one patient). No significant differences between the groups were observed in either the characteristics of the patients or the VMP regimen. The levels of monoclonal protein (M protein) in the control group tended to decrease (with a VMP cycle‑dependency), although they were primarily stable in the concomitant group. During the second and third VMP cycles, the levels of M protein were markedly lower in the control group compared with the concomitant group. All the patients in the control group achieved a partial response, whereas those in the concomitant group exhibited stable disease. Hematological toxicity levels were revealed to be comparable between the two groups, whereas gastrointestinal toxicity was more prevalent in the control group. In conclusion, the results of the present study suggested that the clinical efficacy of melphalan may be reduced by the co‑administration of gastric antisecretory drugs. This interaction may result in decreased toxicity and clinical efficacy of melphalan.

View Figures

View References

1	Raab MS, Podar K, Breitkreutz I, Richardson PG and Anderson KC: Multiple myeloma. Lancet. 374:324–339. 2009. View Article : Google Scholar : PubMed/NCBI
2	Palumbo A and Anderson K: Multiple myeloma. N Engl J Med. 364:1046–1060. 2011. View Article : Google Scholar : PubMed/NCBI
3	Harousseau JL and Moreau P: Autologous hematopoietic stem-cell transplantation for multiple myeloma. N Engl J Med. 360:2645–2654. 2009. View Article : Google Scholar : PubMed/NCBI
4	Shimazaki C: Autologous stem cell transplantation for multiple myeloma: History and future. Int J Myeloma. 3:55–66. 2013.
5	Rajkumar SV, Blood E, Vesole D, Fonseca R and Greipp PR: Eastern Cooperative Oncology Group: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: A clinical trial coordinated by the Eastern cooperative oncology group. J Clin Oncol. 24:431–436. 2006. View Article : Google Scholar : PubMed/NCBI
6	Zonder JA, Crowley J, Hussein MA, Bolejack V, Moore DF Sr, Whittenberger BF, Abidi MH, Durie BG and Barlogie B: Lenalidomide and high-dose dexamethasone compared with dexamethasone as initial therapy for multiple myeloma: A randomized southwest oncology group trial (S0232). Blood. 116:5838–5841. 2010. View Article : Google Scholar : PubMed/NCBI
7	Dimopoulos MA, Chen C, Spencer A, Niesvizky R, Attal M, Stadtmauer EA, Petrucci MT, Yu Z, Olesnyckyj M, Zeldis JB, et al: Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma. Leukemia. 23:2147–2152. 2009. View Article : Google Scholar : PubMed/NCBI
8	Harousseau JL, Attal M, Avet-Loiseau H, Marit G, Caillot D, Mohty M, Lenain P, Hulin C, Facon T, Casassus P, et al: Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: Results of the IFM 2005-01 phase III trial. J Clin Oncol. 28:4621–4629. 2010. View Article : Google Scholar : PubMed/NCBI
9	Richardson PG, Sonneveld P, Schuster M, Irwin D, Stadtmauer E, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, et al: Extended follow-up of a phase 3 trial in relapsed multiple myeloma: Final time-to-event results of the APEX trial. Blood. 110:3557–3560. 2007. View Article : Google Scholar : PubMed/NCBI
10	Ria R, Reale A and Vacca A: Novel agents and new therapeutic approaches for treatment of multiple myeloma. World J Methodol. 4:73–90. 2014. View Article : Google Scholar : PubMed/NCBI
11	Harousseau JL, Palumbo A, Richardson PG, Schlag R, Dimopoulos MA, Shpilberg O, Kropff M, Kentos A, Cavo M, Golenkov A, et al: Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: Analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone. Blood. 116:3743–3750. 2010. View Article : Google Scholar : PubMed/NCBI
12	Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, et al: Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: A meta-analysis. Leukemia. 25:689–696. 2011. View Article : Google Scholar : PubMed/NCBI
13	Palumbo A, Hajek R, Delforge M, Kropff M, Petrucci MT, Catalano J, Gisslinger H, Wiktor-Jędrzejczak W, Zodelava M, Weisel K, et al: Continuous lenalidomide treatment for newly diagnosed multiple myeloma. N Engl J Med. 366:1759–1769. 2012. View Article : Google Scholar : PubMed/NCBI
14	Palumbo A, Bringhen S, Rossi D, Cavalli M, Larocca A, Ria R, Offidani M, Patriarca F, Nozzoli C, Guglielmelli T, et al: Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: A randomized controlled trial. J Clin Oncol. 28:5101–5109. 2010. View Article : Google Scholar : PubMed/NCBI
15	Alexanian R, Haut A, Khan AU, Lane M, McKelvey EM, Migliore PJ, Stuckey WJ Jr and Wilson HE: Treatment for multiple myeloma. Combination chemotherapy with different melphalan dose regimens. JAMA. 208:1680–1685. 1969. View Article : Google Scholar : PubMed/NCBI
16	Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: An overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group. J Clin Oncol. 16:3832–3842. 1998.PubMed/NCBI
17	Ma MH, Yang HH, Parker K, Manyak S, Friedman JM, Altamirano C, Wu ZQ, Borad MJ, Frantzen M, Roussos E, et al: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 9:1136–1144. 2003.PubMed/NCBI
18	Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, et al: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood. 101:2377–2380. 2003. View Article : Google Scholar : PubMed/NCBI
19	Woodhouse KW, Hamilton P, Lennard A and Rawlins MD: The pharmacokinetics of melphalan in patients with multiple myeloma: An intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol. 24:283–285. 1983. View Article : Google Scholar : PubMed/NCBI
20	Bosanquet AG and Gilby ED: Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol. 18:355–362. 1982. View Article : Google Scholar : PubMed/NCBI
21	Ehrsson H, Eksborg S, Osterborg A, Mellstedt H and Lindfors A: Oral melphalan pharmacokinetics-relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother. 6:151–154. 1989.PubMed/NCBI
22	Sviland L, Robinson A, Proctor SJ and Bateman DN: Interaction of cimetidine with oral melphalan. A pharmacokinetic study. Cancer Chemother Pharmacol. 20:173–175. 1987. View Article : Google Scholar : PubMed/NCBI
23	Alberts DS, Chang SY, Chen HS, Evans TL and Moon TE: Oral melphalan kinetics. Clin Pharmacol Ther. 26:737–745. 1979.PubMed/NCBI
24	Tabibi SE and Cradock JC: Stability of melphalan in infusion fluids. Am J Hosp Pharm. 41:1380–1382. 1984.PubMed/NCBI
25	Durie BG, Harousseau JL, Miguel JS, Bladé J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, et al: International Myeloma Working Group: International uniform response criteria for multiple myeloma. Leukemia. 20:1467–1473. 2006. View Article : Google Scholar : PubMed/NCBI
26	Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0, U.S. Department of Health and Human Sciences. National Institutes of Health. National Cancer Institute Published. May 28–2009.v4.03: June 14, 2010.
27	Quinn DI, Nemunaitis J, Fuloria J, Britten CD, Gabrail N, Yee L, Acharya M, Chan K, Cohen N and Dudov A: Effect of the cytochrome P450 2C19 inhibitor omeprazole on the pharmacokinetics and safety profile of bortezomib in patients with advanced solid tumours, non-Hodgkin's lymphoma or multiple myeloma. Clin Pharmacokinet. 48:199–209. 2009. View Article : Google Scholar : PubMed/NCBI
28	Tsukaguchi M, Shibano M, Matsuura A and Mukai S: The protective effects of lafutidine for bortezomib induced peripheral neuropathy. J Blood Med. 4:81–85. 2013. View Article : Google Scholar : PubMed/NCBI
29	Dammann HG, Burkhardt F and Wolf N: The effects of oral rabeprazole on endocrine and gastric secretory function in healthy volunteers. Aliment Pharmacol Ther. 13:1195–1203. 1999. View Article : Google Scholar : PubMed/NCBI
30	Adachi K, Katsube T, Kawamura A, Takashima T, Yuki M, Amano K, Ishihara S, Fukuda R, Watanabe M and Kinoshita Y: CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. Aliment Pharmacol Ther. 14:1259–1266. 2000. View Article : Google Scholar : PubMed/NCBI
31	Bosanquet AG and Gilby ED: Comparison of the fed and fasting states on the absorption of melphalan in multiple myeloma. Cancer Chemother Pharmacol. 12:183–186. 1984. View Article : Google Scholar : PubMed/NCBI
32	Reece PA, Kotasek D, Morris RG, Dale BM and Sage RE: The effect of food on oral melphalan absorption. Cancer Chemother Pharmacol. 16:194–197. 1986. View Article : Google Scholar : PubMed/NCBI